AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

846.233

+14.1041.69%

Number of Gainers:13

Number of Losers:12

Number of Flat:20

PE:- -

High:847.992

Open:828.860

Low:828.659

Close:832.129

Loading ...

ASX Growth Companies With Strong Insider Backing In April 2025

Simply Wall St.

West Pharmaceutical CFO Bernard Birkett to Retire

MT Newswires Live

Cynata Therapeutics to Act as Core Partner in Australian Regenerative Therapy Manufacturing Initiative; Shares Up 3%

MT Newswires Live

What would Warren Buffett do with ASX shares right now?

Imricor Commences VISABL-VT Trial

Exploring 3 Undervalued Small Caps With Insider Buying In Global Markets

Simply Wall St.

Monash IVF Says Brisbane Clinic Incident Not Expected to Impact Share Price; Shares Rise 7%

MT Newswires Live

Monash IVF Group Ltd - Response to ASX Aware Letter

THOMSON REUTERS

Monash IVF Group Ltd - Incident Is Expected to Fall Within Scope of Mvf's Insurance.

THOMSON REUTERS

Monash IVF Group Ltd - Considers That Incident Is an Isolated Incidence of Human Error

THOMSON REUTERS

Why Orthocell, Paladin Energy, Telix, and Woodside shares are racing higher today

BRIEF-Orthocell Says First U.S. Distributors Signed For Remplirs

Guess which ASX All Ords stock is up 10% on big news

Orthocell Appoints First US Distributors for Nerve Repair Product; Shares Rise 6%

MT Newswires Live

BUZZ-Australia's Orthocell rises as co secures US distributors for flagship product

Orthocell - First US Distributors Signed for Remplirs

THOMSON REUTERS

Respiri Changes Name to Vitasora Health

MT Newswires Live

BUZZ-Australia's Proteomics International slides on discounted placement

Proteomics to Raise AU$4.5 Million via Placement; Shares Fall 13%

MT Newswires Live

Mayne Pharma Anticipates FY25 Underlying EBITDA In Range Of A$47 Million To A$51 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":846.2333,"timestamp":1746165599913,"preClose":832.1293,"halted":0,"volume":66164123,"delay":0,"changeRate":0.016949,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":14.104004,"latestTime":"05-02 16:00:00 AEST","open":828.86017,"high":847.99243,"low":828.659,"amount":212079793,"amplitude":0.023234,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746403200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746144000000,1746165600000]],"turnoverRate":0.001833,"increases":13,"decrements":13,"flats":17,"marketCap":134851527200.375,"floatMarketCap":132030281850},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":847.99243,"amplitude":0.023234,"preClose":832.1293,"low":828.659,"latestPrice":846.2333,"volume":66164123,"delay":0,"open":828.86017,"prevYearClose":936.801,"prevWeekClose":799.528,"prevMonthClose":827.414,"prevQuarterClose":815.605,"fiveDayClose":799.528,"twentyDayClose":818.605,"sixtyDayClose":916.519,"secType":"PLATE","market":"AU","turnoverRate":0.001833,"marketCap":134851527200.375,"floatMarketCap":132030281850,"timestamp":1746165599913,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":13,"down":12,"flat":20},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530296775","title":"ASX Growth Companies With Strong Insider Backing In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530296775","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530296775?lang=en_us&edition=fundamental","pubTime":"2025-04-25 03:38","pubTimestamp":1745523499,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a turbulent landscape marked by recent US tariffs on key sectors and fluctuating indices, investors are increasingly focused on identifying resilient growth opportunities. In this context, companies with substantial insider ownership can offer a compelling proposition, as they often signal confidence in long-term potential and alignment with shareholder interests.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 94 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Aussie Broadband is poised for significant earnings growth, projected at 27.6% annually, outpacing the Australian market. Despite a low forecasted return on equity of 10.8%, the company plans to expand through organic growth and mergers and acquisitions, as stated in their recent investor day. Recent board changes include Graeme Barclay joining as a Non-Executive Director, bringing extensive telecommunications e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-growth-companies-strong-insider-193819249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["FLT.AU","BK7096","BK7084","BK7129","XAO.AU","BK7095","BK7093","BK7015","BK7116","UNI.AU","TTT.AU","ACR.AU","ABB.AU","BK7508","BK7077","BK7007","BK7070","NWF.AU","XKO.AU","AVA.AU","CYC.AU","FEX.AU","BK7078","IMA.AU","BBT.AU","PLT.AU","XJO.AU","BK7021","AAL.AU","BK7036"],"gpt_icon":0},{"id":"2529705932","title":"West Pharmaceutical CFO Bernard Birkett to Retire","url":"https://stock-news.laohu8.com/highlight/detail?id=2529705932","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529705932?lang=en_us&edition=fundamental","pubTime":"2025-04-24 22:18","pubTimestamp":1745504339,"startTime":"0","endTime":"0","summary":"West Pharmaceutical Services  said Thursday that Chief Financial Officer Bernard Birkett plans to retire later this year and that a search for his successor is underway.Birkett is expected to remain in the CFO role until a successor is appointed and will then serve as an advisor to support a smooth transition, the company said.West also said it appointed Shane Campbell as chief proprietary segment officer, starting May 5. Campbell most recently served as chief commercial officer of the construction materials business at Carlisle .Shares of West Pharmaceutical Services were down 3.5% in recent trading.Price: 210.50, Change: -7.68, Percent Change: -3.52","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGXZ23171101.USD","SG9999004303.SGD","IE00B64QTZ34.USD","BK4121","BK4585","IE00BYQQ9H92.USD","CSL.AU","LU1169589451.USD","BK4588","BK7511","CSL","BK7508","BK7067","WST","BK4086","BK4567","LU0728928796.USD","LU1169590202.USD","IE00BFXG0V08.USD","BK7501","BK4504"],"gpt_icon":0},{"id":"2529617985","title":"Cynata Therapeutics to Act as Core Partner in Australian Regenerative Therapy Manufacturing Initiative; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529617985","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529617985?lang=en_us&edition=fundamental","pubTime":"2025-04-24 11:47","pubTimestamp":1745466456,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  said it will act as a core partner in the Solutions for Manufacturing Advanced Regenerative Therapies Cooperative Research Center , which recently received Australian Government funding, according to a Thursday filing with the Australian bourse.SMART CRC is a AU$238 million national initiative with over 60 industry, government, healthcare, universities, and research institute partners, the filing said.The partners will now move to draft and execute formal agreements, per the filing.Shares were up 3% in afternoon trade on Thursday.Price : $0.20, Change: $+0.0050, Percent Change: +2.63%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","BK7067","XKO.AU","BK4007","CYP.AU","BK4139","LENZ","BK7508","BK7501","XJO.AU"],"gpt_icon":0},{"id":"2529569525","title":"What would Warren Buffett do with ASX shares right now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529569525","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529569525?lang=en_us&edition=fundamental","pubTime":"2025-04-24 06:39","pubTimestamp":1745447963,"startTime":"0","endTime":"0","summary":"It is fair to say that there's been no shortage of fear on the market lately. Trade tensions, volatility, and headlines predicting the next recession have sent many investors running for the sidelines. But if there's one person who would see today's environment as ripe with opportunity, it is Warren Buffett. While the Oracle of Omaha doesn't typically invest in the ASX, his investment playbook is universal — and it is perfectly suited to moments like these. So, if Buffett were eyeing the ASX today, what might he do?He probably wouldn't even notice. His holding periods often span 20–30 years, and his performance has been built on patience, not prediction. That's a good reminder for any ASX investor. Foolish takeaway Warren Buffett may not be browsing the ASX boards, but his principles can still guide you through turbulent times. Buy quality, ignore the noise, and think long term. In fact, Buffett said it best when he said:  Opportunities come infrequently. When it rains gold, put out th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/24/what-would-warren-buffett-do-with-asx-shares-right-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7511","LU1074936037.SGD","BK7128","LU0648001328.SGD","LU0980610538.SGD","TNE.AU","LU0971096721.USD","LU0154236417.USD","IE000M9KFDE8.USD","BK7016","BK4534","LU0170899867.USD","LU0742534661.SGD","LU1280957306.USD","LOV.AU","IE00BJLML261.HKD","LU0053666078.USD","IE00BWXC8680.SGD","IE00BKDWB100.SGD","LU0683600562.USD","IE00BK4W5M84.HKD","IE00B775SV38.USD","BRK.B","LU0149725797.USD","IE00BK4W5L77.USD","LU0256863811.USD","BK4533","RMD.AU","LU1363072403.SGD","BK7501","LU1914381329.SGD","IE0034235303.USD","BK4588","BK7067","BK7503","LU0787776722.HKD","LU0640476718.USD","BK4585","LU0234570918.USD","LU0417517546.SGD","LU0048573561.USD","BK4581","LU1571399168.USD","IE00B3S45H60.SGD","CSL.AU","LU0130102774.USD","IE00B1XK9C88.USD","BK7508","LU0251131958.USD","BK4550"],"gpt_icon":1},{"id":"2529504436","title":"Imricor Commences VISABL-VT Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2529504436","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529504436?lang=en_us&edition=fundamental","pubTime":"2025-04-23 19:55","pubTimestamp":1745409300,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, April 23, 2025----Imricor Medical Systems, Inc.   is pleased to announce that it has commenced the VISABL-VT clinical trial by completing the first-in-human ventricular ablation guided by real-time MRI with the Company’s NorthStar Mapping System. The procedure was performed by the team at the Amsterdam University Medical Centre , ranked in 2025 by Newsweek as the best hospital in The Netherlands, and in the top 35 worldwide.The procedure marked several world firsts. It was the first ventricular ablation to be guided by real-time MRI, and it was the first left-sided ablation to be performed under real-time MRI guidance. The patient was treated for right-sided and left-sided premature ventricular complexes .Imricor’s Chair and CEO, Steve Wedan, commented, \"We formed Imricor in 2006 with the goal of delivering MRI-compatible catheters and systems that would enable real-time MRI guidance of complex ventricular and atrial ablation procedures, where the power of MRI has the pote","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imricor-commences-visabl-vt-trial-115500347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["AUMC","BK7007","BK7508","BK7503","IMR.AU","VT","BK4585","BK4168","BK4588"],"gpt_icon":0},{"id":"2529504579","title":"Exploring 3 Undervalued Small Caps With Insider Buying In Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2529504579","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529504579?lang=en_us&edition=fundamental","pubTime":"2025-04-23 17:39","pubTimestamp":1745401172,"startTime":"0","endTime":"0","summary":"In recent weeks, global markets have experienced mixed performance, with smaller-cap indexes like the S&P MidCap 400 and Russell 2000 showing gains despite broader market challenges. Economic uncertainty, particularly around trade policies and interest rates, continues to influence investor sentiment across various sectors. In this environment, identifying promising small-cap stocks involves looking for those with strong fundamentals and positive insider activity that may offer potential opportunities amid volatility.Click here to see the full list of 154 stocks from our Undervalued Global Small Caps With Insider Buying screener.Cedar Woods Properties, a smaller company in its sector, shows potential for value with recent insider confidence as William Hames acquired 16,000 shares valued at approximately A$71,200. Despite relying on external borrowing for funding and having a high debt level, the company reported significant growth in sales and net income for the half-year ending Decemb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-3-undervalued-small-caps-093932082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["HIE","BK7145","NEU.AU","BK7508","BK7096","CWP.AU"],"gpt_icon":0},{"id":"2529481575","title":"Monash IVF Says Brisbane Clinic Incident Not Expected to Impact Share Price; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529481575","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529481575?lang=en_us&edition=fundamental","pubTime":"2025-04-23 13:17","pubTimestamp":1745385431,"startTime":"0","endTime":"0","summary":"Monash IVF Group  said that the incident at its Brisbane clinic, where an embryo was mistakenly implanted into the wrong patient, resulting in the birth of a child, will not have a material impact on share price, according to a response to an ASX Aware letter filed on Wednesday.The company said in response to a letter from the ASX that the incident is an isolated incident of human error.MVF confirmed that an internal investigation is ongoing.Shares of the company rose 7% in recent Wednesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7113","BK7508","MVF.AU"],"gpt_icon":0},{"id":"2529517946","title":"Monash IVF Group Ltd - Response to ASX Aware Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2529517946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529517946?lang=en_us&edition=fundamental","pubTime":"2025-04-23 12:34","pubTimestamp":1745382876,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R02L2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7113","MVF.AU"],"gpt_icon":0},{"id":"2529517945","title":"Monash IVF Group Ltd - Incident Is Expected to Fall Within Scope of Mvf's Insurance.","url":"https://stock-news.laohu8.com/highlight/detail?id=2529517945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529517945?lang=en_us&edition=fundamental","pubTime":"2025-04-23 12:34","pubTimestamp":1745382876,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R02L2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7113","BK7508","MVF.AU"],"gpt_icon":0},{"id":"2529351794","title":"Monash IVF Group Ltd - Considers That Incident Is an Isolated Incidence of Human Error","url":"https://stock-news.laohu8.com/highlight/detail?id=2529351794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529351794?lang=en_us&edition=fundamental","pubTime":"2025-04-23 12:34","pubTimestamp":1745382876,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R02L2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MVF.AU","BK7113"],"gpt_icon":0},{"id":"2529290519","title":"Why Orthocell, Paladin Energy, Telix, and Woodside shares are racing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2529290519","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529290519?lang=en_us&edition=fundamental","pubTime":"2025-04-23 10:39","pubTimestamp":1745375981,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1.6% to 7,942.8 points. Four ASX shares that are rising more","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/23/why-orthocell-paladin-energy-telix-and-woodside-shares-are-racing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TLX.AU","BK7508","00495","LHM.AU","BK7509","WDS.AU","XJO.AU","BK1258","PDN.AU","BK1229","BK7067","BK7145","BK7142","OCC.AU","BK7083"],"gpt_icon":0},{"id":"2529945645","title":"BRIEF-Orthocell Says First U.S. Distributors Signed For Remplirs","url":"https://stock-news.laohu8.com/highlight/detail?id=2529945645","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529945645?lang=en_us&edition=fundamental","pubTime":"2025-04-23 09:36","pubTimestamp":1745372186,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Says First U.S. Distributors Signed For RemplirsApril 23 (Reuters) - Orthocell Ltd OCC.AX:FIRST US DISTRIBUTORS SIGNED FOR REMPLIRSFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R02KL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2529551924","title":"Guess which ASX All Ords stock is up 10% on big news","url":"https://stock-news.laohu8.com/highlight/detail?id=2529551924","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529551924?lang=en_us&edition=fundamental","pubTime":"2025-04-23 09:24","pubTimestamp":1745371481,"startTime":"0","endTime":"0","summary":"It has been another good day for owners of Orthocell Ltd  shares. In morning trade, the ASX All Ords stock is up 10% to $1.29. This means that the regenerative medicine company's shares are now up 240% over the past 12 months. Why is this ASX All Ords stock racing higher?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/23/guess-which-asx-all-ords-stock-is-up-10-on-big-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2529796599","title":"Orthocell Appoints First US Distributors for Nerve Repair Product; Shares Rise 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529796599","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529796599?lang=en_us&edition=fundamental","pubTime":"2025-04-23 09:17","pubTimestamp":1745371028,"startTime":"0","endTime":"0","summary":"Orthocell (ASX:OCC) has appointed its first four US distributors operating in Michigan, Virginia, Colorado, and Indiana, for its nerve repair device Remplir, according to a Wednesday filing with the A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","XKO.AU","XAO.AU","XJO.AU","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2529599398","title":"BUZZ-Australia's Orthocell rises as co secures US distributors for flagship product","url":"https://stock-news.laohu8.com/highlight/detail?id=2529599398","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529599398?lang=en_us&edition=fundamental","pubTime":"2025-04-23 09:04","pubTimestamp":1745370269,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Orthocell rises as co secures US distributors for flagship product** Shares of Orthocell OCC.AX rise 8.1% to A$1.27, snap a four-day losing streak ** Stock set for its strongest sessi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL4N3R1037:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2529567258","title":"Orthocell - First US Distributors Signed for Remplirs","url":"https://stock-news.laohu8.com/highlight/detail?id=2529567258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529567258?lang=en_us&edition=fundamental","pubTime":"2025-04-23 07:42","pubTimestamp":1745365343,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R02KL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2529564814","title":"Respiri Changes Name to Vitasora Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2529564814","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529564814?lang=en_us&edition=fundamental","pubTime":"2025-04-23 06:42","pubTimestamp":1745361751,"startTime":"0","endTime":"0","summary":"Respiri  has officially changed its company name to Vitasora Health, per its record with the Australian Securities and Investments Commission, according to a Tuesday filing with the Australian bourse.Trading under the new symbol \"VHL\" is expected to start Thursday, the filing stated. The OTC ticker symbol is also expected to be updated.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","XJO.AU","BK7007","BK7508","RSH.AU","BK7503","XKO.AU"],"gpt_icon":0},{"id":"2529391377","title":"BUZZ-Australia's Proteomics International slides on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2529391377","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529391377?lang=en_us&edition=fundamental","pubTime":"2025-04-22 11:20","pubTimestamp":1745292018,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Proteomics International slides on discounted placement** Proteomics International Laboratories PIQ.AX slides ~10% to A$0.400, lowest since April 7** Stock set for biggest intraday pct loss since February 28** Medical tech co secures commitments to raise A$4.5 mln  via placement at A$0.37/shr, a ~17% discount to last close** Invites eligible shareholders to participate in a share purchase plan to raise additional A$1 million** Says funds will be used to launch its suite of diagnostic tests** About 137,666 shares traded in stock's busiest session since April 8** PIQ loses 50% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nL4N3R006K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PIQ.AU","BK7048"],"gpt_icon":0},{"id":"2529839918","title":"Proteomics to Raise AU$4.5 Million via Placement; Shares Fall 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529839918","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529839918?lang=en_us&edition=fundamental","pubTime":"2025-04-22 11:11","pubTimestamp":1745291479,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories  secured firm commitments from new and existing investors to raise about A$4.5 million through the placement of 12.1 million new fully paid ordinary shares at AU$0.37 per share, according to a Tuesday filing with the Australian bourse.The issue price represents a nearly 18% discount to the 15-day volume-weighted average price, the filing said.Participants will also receive one free attaching option for every two shares subscribed with an exercise price of AU$0.50 per share and an expiry date of May 31, 2026, the filing added.A share purchase plan will also be offered to eligible shareholders on the same terms, to raise an additional AU$1 million, with the possibility of oversubscriptions, the company said.The funds raised will support Promarker test launches in Australia and the US, system upgrades for diagnostics, US lab setups, and general working capital, the company added.Shares of the company fell past 13% in recent Tuesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","XKO.AU","BK7048","BK7508","PIQ.AU","XJO.AU"],"gpt_icon":0},{"id":"2529136294","title":"Mayne Pharma Anticipates FY25 Underlying EBITDA In Range Of A$47 Million To A$51 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2529136294","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529136294?lang=en_us&edition=fundamental","pubTime":"2025-04-22 09:45","pubTimestamp":1745286343,"startTime":"0","endTime":"0","summary":"April 22 (Reuters) - Mayne Pharma Group Ltd ::*IN FY25, ANTICIPATES UNDERLYING EBITDA IN RANGE OF A$47 MILLION TO A$51 MILLION*9-MONTHS UNAUDITED UNDERLYING EBITDA A$28.6 MILLION*SIGNS AGREEMENT WITH ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nRSD8q2vg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLGL","BK7508","BK4007","MYX.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":92,"code":"91000000","status":"200"}]}}